secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2023-03-15T23:59:59+00:00
Accession:  0001104659-23-032800
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion discloses DSE dispute over $300M milestone payments on CLEAR Outcomes data
--------------------------------------------------------------------------------

- NEXLETOL reduced MACE-4 by 13%, MACE-3 by 15%, heart attack by 23%, coronary revascularization by 19% vs placebo.
- Company expects to submit FDA/EMA filings in H1 2023 for label inclusion of CV risk reduction.
- Entitled to $200M-$300M milestone from DSE if EU label includes specific risk reduction; DSE disputes eligibility.
- DSE argues primary endpoint MACE-4 reduction was 12.98%, below 20% threshold; company cites 23% MI reduction.
- Company intends to enforce contractual rights; delay in payment could impact capital needs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000110465923032800/0001104659-23-032800-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000110465923032800/tm239671d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-032800

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer